OLMA: Olema Corp Price/Earnings to Growth Multiple

Symbol and logo of brand Olema Corp (OLMA)

Olema Pharmaceuticals (OLMA) relies on external contractors for drug manufacturing and testing to minimize capital expenditures. The normalized PEG ratio helps filter out market noise, while 0.00 reflects the metric's latest value. The biotech firm aims for dominance in breast cancer therapy via palazestrant, implementing automated compound screening and software robots for data analysis.

Price/Earnings to Growth Ratio: Olema Corp (OLMA) for 07/04/2022 - 11/12/2026

Analytical breakdowns for Olema Pharmaceuticals (OLMA)

- share price and consensus valuation forecast:
Price Performance Chart Olema Pharmaceuticals, Inc.|OLMA - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Olema Pharma|OLMA - Enterprise Value
- book value of equity indicators:
Book Value per Share Olema Pharmaceuticals|OLMA - Company Book Value|Capitalization to Book Value Ratio olema.com|OLMA - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Olema Pharmaceuticals|OLMA - Long-Term Debt to Capital|Current Liabilities to Capital olema.com|OLMA - Company Debts|Debt to Net Assets Ratio Olema Pharma|OLMA - Company Long-Term Debt|Short-Term Debt Olema Pharmaceuticals|Quick Liquidity olema.com
- company profitability and valuation multiples indicators:
OLMA - Net Profit|Expected Net Profit Olema Pharmaceuticals|OLMA - Price to Earnings Ratio|Projected Price to Earnings Olema Corp|OLMA - PEG Multiple|EV/EBITDA Multiple Olema Pharma|OLMA - Operating profit before deduction of amortization|Earnings per share for the trailing year Olema Pharmaceuticals|OLMA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months olema.com|OLMA - Earnings growth in current year|Expected earnings per share trend next year Olema Pharmaceuticals
Fundamental company analysis:Olema Pharmaceuticals, Inc., OLMA
Original product of Olema Pharma

When selecting undervalued assets, the ratio of market value to earnings growth is critical, where a value below one signals potential price appreciation. In the case of Olema Pharmaceuticals (OLMA), the anticipation of Phase III trial results for its oncology drug makes the analysis of P/E relative to EPS growth rates key, as this metric weighs current losses against the business's future expansive growth.

Competitors of Olema Pharmaceuticals

PBYI (pumabiotechnology.com) - Growth-Adjusted Payback Ratio|PEG Multiple GLSI (Greenwich LifeSciences, Inc)|ZNTL - Price/Earnings to Growth Multiple|MacroGenics, Inc. - PEG Multiple|PSTV - PEG Multiple|processapharmaceuticals.com (PCSA) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio EGRX